key: cord-0829919-j3n1istf
authors: Sakalli, Erdal; Temirbekov, Dastan; Bayri, Esra; Alis, Esra Ergun; Erdurak, Selcuk Cem; Bayraktaroglu, Mesut
title: Ear nose throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients
date: 2020-06-23
journal: Am J Otolaryngol
DOI: 10.1016/j.amjoto.2020.102622
sha: 474fe38cccb4d98985829c6a2149a2d71f681a86
doc_id: 829919
cord_uid: j3n1istf

PURPOSE: To determine the frequency and severity of general and ear nose throat (ENT)- related symptoms, especially smell and/or loss of sense of taste (STL) in COVID-19 disease, as well as to investigate the recovery process of STL. MATERIALS AND METHODS: Patients with a positive COVID-19 diagnosis were given a questionnaire consisting of general questions (age, sex, date of symptoms, smoking history, concomitant diseases), questions about the most obvious symptom at presentation (one option only), the severity and frequency of symptoms (general and ENT), and STL (recovery time and degree of recovery). RESULTS: The study population consisted of 172 patients, 18–65 years old (mean age, 37.8 ± 12.5 years; 51.2% female; 76.2% nonsmokers). Cough (n = 30, 17.4%) and loss of sense of smell (n = 18, 10.4%) were the most obvious general and ENT symptoms, respectively. Eighty-eight patients (51.2%) reported loss of sense of smell, and 81 patients (47.1%) reported loss of sense of taste. The mean recovery times for loss of sense of smell and loss of sense of taste were 8.02 ± 6.41 and 8.20 ± 7.07 days, respectively. The loss of sense of smell and loss of sense of taste were the unique symptoms in four (4.54%) and one (1.23%) patients, respectively. CONCLUSION: STL is a common symptom in COVID-19 and may be the first and/or only symptom of this disease. In patients presenting with STL complaints, surveillance for possible COVID-19 disease and screening tests will facilitate the struggle against the disease.

J o u r n a l P r e -p r o o f

The virus responsible for COVID-19 disease, SARS-CoV-2, is a novel member of the coronavirus family that appeared in the Hubai region of China in late 2019 and rapidly became a pandemic affecting the world. Although this virus can cause severe respiratory failure and even death in infected patients, it has spread rapidly and continues to spread among people because it can cause mild or no symptoms in the majority of cases (1, 2) . The most effective method for preventing the spread of the virus is the early detection and isolation of infected individuals.

The most common symptoms of COVID-19 are fever, cough, myalgia, fatigue, and difficulty breathing. In addition, ear, nose, and throat (ENT) symptoms, including loss of sense of smell and/or loss of sense of taste (STL) have been reported as symptoms caused by the virus (3, 4) . Rhinoviruses, Epstein-Barr virus, parainfluenza virus, and some coronaviruses have been shown to cause upper respiratory infections, nasal congestion, and rhinorrhea, and may result in STL. Although the pathophysiology of STL developing after infection with these viruses is not yet clear, it has been suggested to be due to olfactory epithelial damage by the virus or its spread to the central nervous system (5, 6) . There are increasing reports of SARS-CoV-2 causing STL both anecdotally and in the peer-reviewed medical literature. However, it has been reported that infection with SARS-CoV-2 may cause STL without nasal discharge and/or nasal congestion or any other symptoms in some patients, unlike other viruses that infect the upper respiratory tract (7, 8) . The behavior of SARS-CoV-2 in some patients is contrary to observations in other patients. This prevents suspicion of the disease clinically, delays diagnosis and isolation of patients infected with the virus and, therefore, makes it difficult to deal with the disease. Therefore, knowing the full range of possible symptoms associated with the virus is the first and most important step in identifying infected patients.

J o u r n a l P r e -p r o o f

Analysis of patients' symptoms focusing on STL with confirmed polymerase chain reaction (PCR)-positive testing for the SARS-CoV-2 viral genome was conducted during the COVID-19 outbreak in Turkey. Patients treated at the Istanbul Aydin University, Faculty of Medicine, Istanbul, Turkey, were included in the study. In addition, many other patients and health workers (nurses, physicians, etc.) with confirmed positive PCR test results were voluntarily enrolled in the study. The study protocol was approved by the Ethics Committee of Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine (number: 83045809-604.01.02). All subjects provided informed consent to participation in the study. The exclusion criteria were as follows: age < 18 years old, failure to complete the whole questionnaire, STL before the COVID-19 outbreak, no confirmed positive PCR test result, recent commencement of treatment with new drugs, a history of chronic nasal problems and recent head injury or brain and/or nose operations, severe respiratory failure, or in the intensive care unit. Therefore, we mainly studied patients with mild-to-moderate symptoms with a positive COVID-19 test result without severe respiratory failure.

A questionnaire survey was administered among the patients in the outpatient room or by telephone for some outpatients and health workers with SARS-CoV-2 infection. In addition, an online questionnaire (Professional Survey Monkey, San Mateo, CA) was sent by e-mail to patients who could not be reached by telephone. The questionnaire consisted of general questions regarding age, sex, date of symptoms, smoking history and concomitant diseases; questions about the most obvious symptoms at presentation (one option only) and questions about severity and frequency of symptoms during illness (general and ENT symptoms including STL associated with SARS-CoV-2 infection); and questions regarding recovery time and degree of recovery of STL.

J o u r n a l P r e -p r o o f

A total of 175 patients answered all questions during the study period. Three patients were excluded from the analysis-two had chronic STL due to chronic rhinosinusitis, and one had undergone nose surgery 10 days before the COVID-19 outbreak. Therefore, the final analysis was performed in 172 patients. The patients ranged in age from 18 to 65 years (37.8 ± 12.5 years), 51.2% were female, and 76.2% were nonsmokers. The mean time to diagnosis after onset of symptoms was 4.3 ± 3.2 days ( Table 1 ). The most prevalent comorbidities in these patients were allergic rhinitis in 8%, high blood pressure in 5%, depression in 4%, asthma in 3%, diabetes in 3%, renal disease in 2%, thyroid diseases in 2%, heart problems in 2%, and autoimmune diseases in 2%. There were no significant associations between comorbidities and STL.

The most obvious symptoms of patients at presentation were cough (n = 30, 17.4%), fatigue (n = 25, 14.5%), fever (n = 24, 13.1%), loss of sense of smell (n = 18, 10.4%), headache (n = 17, 9.88%), myalgia (n = 16, 9.8%), difficulty breathing (n = 15, 8.72%), loss of sense of taste (n = 11, 6.40%), sore throat (n = 4, 2.32%), diarrhea (n = 4, 2.32%), nasal obstruction (n = 3, 1.74%), need to blow the nose (n = 2, 1.16%), rhinorrhea (n = 2, 1.16%), and postnasal discharge (n = 1, 0.58%) ( Table 1) .

The severity and frequency of general symptoms during Covid-19 disease are shown in Table 2 . Cough, fatigue, fever, headache, myalgia, and difficulty breathing were the most common symptoms. The severity and frequency of ENT symptoms during COVID-19 disease are shown in Table 3 .

Eighty-eight patients (51.2% of total; 44 females, 50%) were reported to have loss of sense of smell related to SARS-CoV-2 infection. Among them, loss of sense of smell was mild in one (1.2%) patient, moderate in 24 (14%), and severe in 62 (36.0%) ( Table 3 ). The loss of sense of smell was the only symptom in four (4.54%) patients, and these patients did not develop any other symptoms during the period of the disease. The loss of sense of smell appeared after, before, or simultaneously with the appearance of other symptoms of SARS-CoV-2 infection in 23 (26.1%), 19 (21.5%), and 46 (52.2%) cases, respectively. Forty-five (51.1%) patients with loss of sense of smell had neither nasal obstruction nor rhinorrhea.

J o u r n a l P r e -p r o o f

The mean age of patients was significantly younger in the loss of sense of smell group than the no loss of sense of smell group (35.0 ± 11.3 years vs. 40.8 ± 13.1 years, respectively, p < 0.05). The rate of smoking was higher in the loss of sense of smell group than the no loss of sense of smell group but the difference was not statistically significant (26 [29.5%] vs. 15 [17.9%], respectively, p = 0.072). There was a significant positive association between loss of sense of smell and taste (p < 0.001). In addition, the rates of the symptoms of the need to blow the nose, nasal obstruction, rhinorrhea, fatigue, myalgia, fever, facial pain, and headache were significantly higher in the loss of sense of smell group than the no loss of sense of smell group (all p < 0.05). There were no statistically significant associations of other symptoms with or without loss of sense of smell (all p > 0.05) ( Figure 1 ). Similar results were observed for loss of sense of taste (p < 0.001). The average time for recovery of the sense of smell was 8.02 ± 6.41 days (Table 4 ).

Eighty-one patients (47.1% of total; 43 females, 53.08%) had loss of sense of taste related to SARS-CoV-2 infection. Among them, loss of sense of taste was mild in 11 (6.4%) patients, moderate in 18 (10.5%), and severe in 52 (30.2%) ( Table 3 ). The loss of sense of taste was the only symptom in one (1.23%) of these patients. While nine (11.1%) of the patients who described a loss of sense of taste did not describe loss of sense of smell, the remaining 72 (88.8%) patients described loss of the senses of both smell and taste together. Among these latter 72 patients, the loss of sense of taste appeared after (n = 14, 19.4%), before (n = 6, 8.33%), or at the same time as the appearance of the loss of sense of smell (n = 52, 72.2%). (Table 4 ).

Patients infected with SARS-CoV-2 present with a wide range of ENT-related and/or general symptoms, with new symptoms added to the list every day. In recent weeks, both published articles and anecdotal reports on COVID-19 have indicated that the virus may also cause STL. Here, we investigated the frequency and severity of ENT-related and general symptoms in patients with confirmed SARS-CoV-2 infection, the relationships between STL and other symptoms, and the recovery process of STL.

The rapid increase in the number of patients infected with SARS-CoV-2 and in deaths due to infection place a major burden on the healthcare systems of countries struggling with the disease. Success against COVID-19 disease requires early detection and isolation of infected patients. Therefore, it is very important to determine the probabilities of all symptoms caused by the disease (1,2) . Previous studies showed that COVID-19 disease causes a number of general symptoms, such as difficulty in breathing, myalgia, fatigue, fever, and cough. In more severe cases, it may lead to viral pneumonia and acute respiratory distress syndrome (ARDS), which may require hospitalization for treatment and follow-up. However, it may still result in death despite treatment (3, 4) .

In a meta-analysis involving five studies evaluating general and upper respiratory tract symptoms of patients hospitalized due to COVID-19 disease in Asian countries, it was reported that 85.6% of patients had fever, 68.7% had cough, and 39.4% had fatigue as the main symptom on admission to hospital, while 12.4% of patients had pharyngodynia, and 3.7% had nasal congestion and upper respiratory tract symptoms. The authors stated that rhinorrhea and sore throat are very rare in patients infected with SARS-CoV-2 , and STL was not seen. They warned that other upper respiratory tract symptoms, especially STL, are rare as the articles they examined included hospitalized SARS-CoV-2-positive patients and, therefore, symptoms such as STL, nasal congestion, and sore throat may be complaints in patients infected with SARS-CoV-2 (9). Similarly, in a study comparing the loss of sense of smell in hospitalized vs. non-hospitalized SARS-CoV-2-positive patients, the rate of loss of sense of smell was approximately five times higher among outpatients than inpatients. The authors argued that this difference may be due to the reduced sensitivity to loss of sense of smell in patients due to factors such as respiratory distress in patients hospitalized for COVID-19 disease (10).

More than 80% of patients infected with SARS-CoV-2 survive the disease with mild symptoms, and patients with mild presentation can show a number of very different symptoms (11). In a study including only SARS-CoV-2 positive patients with mild symptoms in Italy in which the participants were asked about their general symptoms over the telephone, and the Sino-nasal Outcome Test-22 (SNOT-22) was performed, the most common symptoms were fever (55.9%), cough (60.4%), and fatigue (68.3%). The most common upper respiratory tract symptoms were nasal congestion (41.1%), sore throat (31.2%), and STL (64.4%) (12). In the present study in patients with mild or moderate symptoms, the most common general symptoms were myalgia In a study conducted on the Internet in patients with upper respiratory tract infection who had been tested for SARS-CoV-2, 68% of patients who were confirmed to have SARS-CoV-2 by PCR described loss of sense of smell and 71% described loss of sense of taste, while 16% and 17% of patients negative for SARS-CoV-2 J o u r n a l P r e -p r o o f described loss of the sense of smell and taste, respectively (17). The frequency of STL has been reported be at least 10 times higher in SARS-CoV-2-positive patients than in uninfected individuals, and there is a strong association between loss of sense of smell and loss of taste. In the above study, loss of sense of smell was the main reason for admission to hospital in 22% of SARS-CoV-2-positive patients, and 72.5% of patients who received no treatment for STL recovered, with the majority recovering within the first 2 weeks (17). The data obtained with the COVID-19 Anosmia Reporting Tool developed by the American Academy of Otolaryngology-Head and Neck Surgery for clinicians indicated that 73% of 237 SARS-CoV-2-positive patients had loss of sense of smell at admission to hospital, and 26.6% of these patients had loss of sense of smell as the main complaint at the time of admission to hospital. It was reported that 85% of the patients who described loss of sense of smell recovered within the first 10 days, and the average recovery time was 7.2 days (18). In a study conducted in 417 SARS-CoV-2-positive patients with mild or moderate symptoms, 85.6% of patients described loss of sense of smell, 88.8% described loss of taste, and 79.6% of those with loss of sense of smell had anosmia and 78.4% reported that they had ageusia. The report also stated that 67.8% of patients with loss of sense of smell and 78.9% of patients with loss of sense of taste recovered to various degrees within an average of 8 days (19) . In the present study, we found that 36% of the patients who described various degrees of loss of sense of taste (52.2% of the total) had anosmia. In addition, we found that 30.2% of the patients who described various degrees of loss of sense of taste (47.1% of the total) had ageusia. Among our patients who described loss of sense of smell, 78.4% improved to various degrees within an average of 8.02 ± 6.41 days. In 77.8% of our patients who described loss of taste, we found that the loss of sense of taste improved to various degrees within an average of

Hopkins The English in this document has been checked by at least two professional editors, both 

Clinical characteristics of coronavirus disease 2019 in China

Characteristics of and important lessons from the coronavirus disease

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Overview of the novel coronavirus (2019-nCoV): The pathogen of severe specific contagious pneumonia (SSCP)

Identification of viruses in patients with postviral olfactory dysfunction

The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system

Coincidence of Covid-19 epidemic and olfactory dysfunction outbreak. medRxiv

Olfactory Dysfunction: A Highly Prevalent Symptom of COVID-19

With Public Health Significance. Otolaryngol Head Neck Surg